Correlations Between Shoulder Rotational Motion, Strength Measures and Throwing Biomechanics in Collegiate Baseball Pitchers

Pitching involves high stresses to the arm that may alter soft tissue responsible for controlling biomechanics. It has been hypothesized that imbalances in strength and flexibility of the dominant shoulder lead to decreased performance and increased injury risk, but it is not fully known what specific pitching biomechanics are altered. There is a critical need to determine correlations between shoulder rotational strength, range of motion and pitching kinetics. Without such knowledge, identifying potential for injury from shoulder imbalances will likely remain difficult and invasive. The goal of this study was to determine correlations between shoulder rotational strength and range of motion and kinetics. Twelve collegiate pitchers participated in this IRB approved study. The clinical measures session tested shoulder rotational range of motion and strength and grip strength. The motion analysis session tested pitching biomechanics. Paired t-tests investigated differences in strength and range of motion between arms. Linear regression was performed to determine correlations between clinical measures, kinetics and pitch velocity. Regression learner neural networks were created to predict pitch velocity and elbow varus torque using clinical measures as inputs. The dominant arm had significantly higher external rotation and total range of motion than the nondominant arm. The nondominant arm normalized external rotation peak torque was significantly greater than the dominant arm at 0˚ external rotation. Correlations were found between elbow varus torque and isometric external/internal rotation ratio, and between shoulder posterior shear force and isokinetic eccentric external rotation/internal rotation ratios. Correlations to velocity included grip strength, concentric external rotation peak torque, isometric internal rotation peak torques, and isometric external rotation peak torques. The neural network accurately predicted velocity, with the standard deviation of the error equal to 2.29 (2.97%). These correlations associate two testing methods to identify injury risk. Increasing external/internal rotation ratios may decrease elbow varus torque and shoulder posterior shear force. Increasing external rotation, internal rotation, and grip strength may lead to velocity gains. Velocity can be predicted using clinical measures and a neural network

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Relationships Among Shoulder Rotational Strength, Range of Motion, Pitching Kinetics, and Pitch Velocity in Collegiate Baseball Pitchers

Cross, JA, Higgins, AW, Dziuk, CC, Harris, GF, and Raasch, WG. Relationships among shoulder rotational strength, range of motion, pitching kinetics, and pitch velocity in collegiate baseball pitchers. J Strength Cond Res XX(X): 000–000, 2022—Throwing shoulder injuries are the most common type of injury experienced by baseball pitchers. Weakness in the shoulder musculature and insufficient throwing arm range of motion are both risk factors for developing a shoulder injury. The goal of this study was to determine correlations among shoulder rotational strength, range of motion, pitching kinetics, and pitch velocity in collegiate pitchers. Thirteen uninjured male college pitchers were evaluated. Clinical measures included shoulder internal and external rotation range of motion, peak isokinetic internal and external rotator strength, and peak isometric internal and external rotator strength. Three-dimensional biomechanics were assessed as subjects threw from an indoor pitching mound to a strike zone net at regulation distance. Pearson\u27s correlations were used to assess the associations among the clinical measures and throwing metrics. Five significant correlations were found between peak shoulder compressive force and strength, and 4 significant correlations were found between pitching velocity and strength (p \u3c 0.05). No significant correlations were found between range of motion and pitching kinetics or velocity. Our results suggest that as shoulder rotational strength increases, the peak shoulder compressive force and pitch velocity both increase. Knowledge of relationships between strength metrics and pitching biomechanics may allow for improved strength training routines with the goal of increasing velocity without increasing injury risk